

C1s/C1-INH and MASP-1/C1-INH complex assays

Tools to investigate and unravel early complement activation in complement-mediated diseases

Early intervention

Complement-mediated inflammation is linked to a wide variety of diseases. In some cases, it is important to intervene as early as possible in this process as it has direct clinical implications. Currently C1-INH administration in its natural or recombinant form is an approved treatment for hereditary angioedema (HAE).

C1-INH or other early complement inhibitors are investigated for better targeted therapies in pending clinical studies. Hence the C1-INH complexes can be used as an indirect marker for ongoing classical or lectin pathway activation.



Why looking at C1-INH and its complexes?

C1-INH administration is an approved common treatment for hereditary angioedema (HAE) and in clinical trials for:

- Prevention of rejection in kidney transplantation
- Traumatic brain injury and acute ischemic stroke
- Endotoxemia, sepsis, inflammation and multiple organ failure
- Application in end stage renal disease and chronic kidney disease

Benefits

- ✓ Validated in COVID-19 and MIS-C studies
- ✓ Ready-to-use ELISA's with a working time of 1 hour and 45 minutes
- ✓ Reliable quantification of C1s/C1-INH complex or MASP-1/C1-INH complex
- ✓ Uses EDTA-plasma as input sample. No need for complement-preserved serum to assess early lectin pathway activation
- ✓ First on the market available ELISA assay to measure early classical and early lectin pathway activation



How to order and start

Get yourself both ELISA kits and start your research. To order the:

1. C1s/C1-INH assay use cat. #HK399
2. MASP-1/C1-INH assay use cat. #HK3001

Go to www.hycultbiotech.com and order the kits via your local distributor. Also check our other complement tools and discover the possibilities.

Together, we improve health.
Collaborate to achieve success,
your goal is our goal.